FAP and pancreatic adenocarcinoma: Using the TCGA dataset we analysed the survival of patients who we expect to have greater prevalence of the novel CAF-S5 (based on bulk high expression of FAP and PDPN in the patient and low αSMA) across four solid organ cancers: liver hepatocellular, pancreatic adenocarcinoma, breast invasive carcinoma and renal clear cell carcinoma (Fig. 6e, cox regression analysis shown in Supplementary Fig. 4C).